On June 13, 2023, the second "West Beijing Development Forum" themed "Transforming and Nurturing New Opportunities: focus on West Beijing" was held in Shijingshan District, Beijing, at the Shougang Park. Attendees of the forum were guests from the government, corporate organizations, and authoritative media, who participated in discussions and dialogues, jointly discussing the high-quality transformation of West Beijing. The forum showcased the achievements of the region's industrial transformation in recent years and it also included a series of strategic collaborations and project signings. Over 60 enterprises, including Baheal Pharmaceutical Group and its nurtured high-end medical equipment enterprise, Huake Pioneer, signed various agreements with the "two districts and two enterprises" (Shijingshan District and Mentougou District, Shougang Group and Jingneng Power Co., Ltd) for strategic cooperation, company settlement, and project landing.

The forum, jointly hosted by the Beijing Municipal Development and Reform Commission and the "Two Districts, Two Enterprises", focuses on the overall development of western Beijing. It promotes deep integration between districts and enterprises, further strengthening the unified strategic planning of the region.

At the forum, Li Zhen, President of Baheal Investment Group, signed a letter of intent to cooperate with Lv Chenfei, Deputy Secretary and Mayor of Mentougou District, Beijing. The two parties intend to establish the "Baheal & Mentougou Great Health Innovation Investment Fund". The Fund will mainly invest in and incubate innovative enterprises in fields such as innovative drugs, high-end medical devices, and more. In addition, Xu Huijun, Chairman of Beijing Huake Pioneer Medical Devices Co., Ltd. also signed a letter of intent to invest with the Mentougou District Government of Beijing at the forum.

It's revealed that the People's Government of Mentougou District, Beijing, and Zhongguancun Development Group have jointly established the West Beijing Industry Guidance Fund of Mentougou District, Beijing, with a focus on key investments in hard tech directions such as artificial intelligence and health and medicine. As a specialized subsidiary of this fund aimed at layout in the segmented healthcare industry, the "Baheal & Mentougou Great Health Innovation Investment Fund" will be managed by an equity investment fund management company under Baheal Investment Group, which is dedicated to health industry innovation investment.

The management team will leverage Baheal's platform for integrating technological innovation resources, industrial background, and team expertise to empower innovation and industry cultivation through the fund. Given the larger context of rapid breakthroughs and innovative development in the health sector, the establishment of the "Baheal & Mentougou Great Health Innovation Investment Fund" helps to further amplify the cluster effect of the health and medical industry. It boosts the vibrant development of strategic emerging industries in Mentougou and spurs innovative breakthroughs in high-quality industrial resources.

Huake Pioneer, involved in the signing this time, is a high-end medical device company incubated by Baheal. Huake Pioneer specializes in providing radiation therapy solutions for patients with full-body tumors and atrial fibrillation, using globally leading medical linear accelerators. The company possesses cutting-edge spherical radiation technology and is dedicated to the research and development of world-class medical linear accelerators and related software. This signing will inject new energy into Huake Pioneer's independent innovation.

As a health industry group driven by technological innovation, Baheal focuses on three major fields: innovative drugs, high-end medical devices, and technology transformation platforms. It works hand in hand with national research institutes for innovative incubation, and has made positive progress in innovative areas such as artificial hearts, medical linear accelerators, medical high-definition endoscopes, medical artificial intelligence, oncology and bone regeneration innovative drugs, early screening of major diseases and accompanying drug diagnosis, and high-end sustained-release formulations. Since the Baheal Medical Research Results Transformation Base settled in Mentougou in 2022, Baheal has fully utilized its innovative resource integration capabilities and its capacity to incubate as a leading company in the health industry. In close collaboration with the Mentougou district, Baheal has gathered various innovative resource elements, providing powerful momentum for the construction of regional industrial highlands and promoting innovation in the industry

In the future, Baheal will continue to deepen its strategic partnership with the Mentougou district, constantly exploring new ways to support the transformation of scientific and technological innovations. The aim is to facilitate the settlement of more high-quality medical health projects in Mentougou, thereby contributing to the innovative development of the medical and health industry.